NCT06747026Completed
Real-World Immuno-Radiotherapy for Advanced NSCLC
Real-world Survival Outcomes and the Evaluation of Optimal Strategies for Immuno-Radiotherapy in Advanced Non-Small-Cell Lung Cancer: a Territory-wide Study (OCEANUS Study)
Source: ClinicalTrials.gov · Last updated 24 Dec 2024
Brief summary (registry, in English)
The optimal combination strategy for radiotherapy combined with immunotherapy (iRT) in advanced non-small-cell lung cancer (NSCLC) remains unclear, and there is a lack of real-world data to validate its efficacy. The objective of this study is to confirm the survival benefits of iRT in advanced NSCLC and to identify the optimal combination strategy for its use.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 338 (actual)
- First submitted
- 18 Dec 2024
- Start date
- 1 Jan 2015
- Primary completion date
- 1 Dec 2024
- Lead sponsor
- Fengming Kong
- Diseases
- Lung cancer
- NCT number
- NCT06747026
What you commit to
- Study type: Observational
- Participants enrolled: 338
- From 1 Jan 2015 to the primary completion date, 1 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who did not receive radiotherapy or who did not undergo radiotherapy within 90 days before or after immunotherapy
Other illness
- Patients with multiple primary cancers or a pathological diagnosis of small cell lung cancer
Who the study is looking for
- NSCLC patients who received immunotherapy between 2015 and 2021
- For unresectable locally advanced NSCLC: definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT or concurrently with RT
- For de novo metastatic NSCLC: radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT or concurrently with RT
- For post-treatment progressive NSCLC: salvage radiotherapy must have been performed during immunotherapy or within 90 days after the cessation of immunotherapy
- Age \>= 18 years old
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Queen Mary Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.